Acute Lymphoblastic Lymphoma

Relapsed or Refractory

CCT5079
Phase Ib Study of Braxucabtagene Autoleucel plus Dasatinib in Adults with Acute Lymphoblastic Leukemia
PI: Muffy Sponsor: Stanford University

CCT5078
Phase Ib/II Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
PI: Frank Sponsor: Stanford University

CCT5084
Phase III Dose-Exploration & Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed / Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
PI: Weng Sponsor: Beam Therapeutics Inc.

KEY
Pending
Open for Enrollment  Link  Optional Path
Extension Study  Immunotherapy
Observational Study  Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu